Aurora Cannabis (ACB) will struggle to grow in the near future
Aurora Cannabis (ACB) currently trades at $0.84 and has grown by 4.22% today. The company’s net revenue was 56 million Canadian dollars, representing a 25.5% sequential decrease. Aurora recorded a loss from operations of CA$119.6 million and a net loss of CA$1.3 billion. And the company’s performance in the first quarter wasn’t much better. During the second quarter, Aurora’s goodwill was CA$2.4 billion. Aurora may have to incur significant write-downs in the future, which would hurt its bottom line. And considering the company is far from profitable, this is something investors should keep in mind.
Based on this information, investorsQ rates this stock 4 out of 10. We give it this rating based on current information written in this article. The high forecast for Aurora Cannabis is $3.00 and the low is $0.30. Notably, the company’s market cap is $967.12 million with a 52 week high of $9.37 and a 52 week low of $0.60. ACB went up to $0.03 from the previous closing price of $0.81. ACB has changed in price by -8.19 per share in the last 12 months.
Aurora Cannabis Inc., through its subsidiaries, is engaged in the production and distribution of medical cannabis. The Company is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering, and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, and home cultivation.